Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Journal of Gastroenterology and Hepatology|November 3, 2010
Economic evaluation of sorafenib in unresectable hepatocellular carcinomaBrian I Carr, Stuart Carroll, Noemi Muszbek, et al.Pharmacoeconomics|May 16, 2013
Overview of parametric survival analysis for health-economic applicationsK Jack Ishak, Noemi Kreif, Agnes Benedict, et al.Journal of Comparative Effectiveness Research|August 29, 2023
Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of careNeil Hawkins, Noemi Muszbek, Rachel Evans, et al.Journal of Comparative Effectiveness Research|June 20, 2023
Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphomaNoemi Muszbek, Edit Remak, Qian Xin, et al.Rheumatology and Therapy|September 29, 2017
Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer PerspectiveRebekah H Borse, Chloe Brown, Noemi Muszbek, et al.Current Medical Research and Opinion|May 9, 2012
Modelling survival in hepatocellular carcinomaNoemi Muszbek, Noemi Kreif, Adriana Valderrama, et al.The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|January 24, 2007
Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysisAndrew J Palmer, William J Valentine, Joshua A Ray, et al.Journal of Comparative Effectiveness Research|June 9, 2022
Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndromeNeil Hawkins, Noemi Muszbek, Rachel Evans, et al.Current Medical Research and Opinion|November 27, 2008
Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in CanadaNoemi Muszbek, Sonalee Shah, Stuart Carroll, et al.Blood Pressure. Supplement|August 19, 2008
Public health value of fixed-dose combinations in hypertensionLuis M Ruilope, Michel Burnier, Noemi Muszbek, et al.Pageof 2